α-conotoxins ImI and ImII target distinct regions of the human α7 nicotinic acetylcholine receptor and distinguish human nicotinic receptor subtypes

Michael Ellison, Fan Gao, Hai Long Wang, Steven M Sine, J. Michael McIntosh, Baldomero M. Olivera

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The Conus peptides α-conotoxin ImI (α-ImI) and ImII (α-Imll) differ by only three of 11 residues in their primary sequences and yet are shown to inhibit the human α7 nicotinic acetylcholine receptor (nAChR) by targeting different sites. Mutations at both faces of the classical ligand binding site of the α7 nAChR strongly affect antagonism by α-ImI but not α-ImII. The effects of the mutations on α-ImI binding and functional antagonism are explained by computational docking of the NMR structure of α-ImI to a homology model of the ligand binding domain of the α7 nAChR. A distinct binding site for α-ImII is further demonstrated by its weakened antagonism for a chimeric receptor in which the membrane-spanning domains and intervening linkers of the α7 nAChR are replaced with the corresponding sequence from the serotonin type-3 receptor (5HT3). The two toxins also discriminate between different subtypes of human nicotinic receptors; α-ImII most strongly blocks the human α7 and α1β1δε receptor subtypes, while α-ImI most potently blocks the human α3β2 subtype. Collectively, the data show that while α-ImI targets the classical competitive ligand binding site in a subtype selective manner, α-ImII is a probe of a novel inhibitory site in homomeric α7 nAChRs.

Original languageEnglish (US)
Pages (from-to)16019-16026
Number of pages8
JournalBiochemistry
Volume43
Issue number51
DOIs
StatePublished - Dec 28 2004

Fingerprint

Conotoxins
Nicotinic Receptors
Binding Sites
Ligands
Receptors, Serotonin, 5-HT3
Mutation
Competitive Binding
Nuclear magnetic resonance
Membranes
Peptides

ASJC Scopus subject areas

  • Biochemistry

Cite this

α-conotoxins ImI and ImII target distinct regions of the human α7 nicotinic acetylcholine receptor and distinguish human nicotinic receptor subtypes. / Ellison, Michael; Gao, Fan; Wang, Hai Long; Sine, Steven M; McIntosh, J. Michael; Olivera, Baldomero M.

In: Biochemistry, Vol. 43, No. 51, 28.12.2004, p. 16019-16026.

Research output: Contribution to journalArticle

Ellison, Michael ; Gao, Fan ; Wang, Hai Long ; Sine, Steven M ; McIntosh, J. Michael ; Olivera, Baldomero M. / α-conotoxins ImI and ImII target distinct regions of the human α7 nicotinic acetylcholine receptor and distinguish human nicotinic receptor subtypes. In: Biochemistry. 2004 ; Vol. 43, No. 51. pp. 16019-16026.
@article{62dbd1f4a77f47879a407a1c4126d890,
title = "α-conotoxins ImI and ImII target distinct regions of the human α7 nicotinic acetylcholine receptor and distinguish human nicotinic receptor subtypes",
abstract = "The Conus peptides α-conotoxin ImI (α-ImI) and ImII (α-Imll) differ by only three of 11 residues in their primary sequences and yet are shown to inhibit the human α7 nicotinic acetylcholine receptor (nAChR) by targeting different sites. Mutations at both faces of the classical ligand binding site of the α7 nAChR strongly affect antagonism by α-ImI but not α-ImII. The effects of the mutations on α-ImI binding and functional antagonism are explained by computational docking of the NMR structure of α-ImI to a homology model of the ligand binding domain of the α7 nAChR. A distinct binding site for α-ImII is further demonstrated by its weakened antagonism for a chimeric receptor in which the membrane-spanning domains and intervening linkers of the α7 nAChR are replaced with the corresponding sequence from the serotonin type-3 receptor (5HT3). The two toxins also discriminate between different subtypes of human nicotinic receptors; α-ImII most strongly blocks the human α7 and α1β1δε receptor subtypes, while α-ImI most potently blocks the human α3β2 subtype. Collectively, the data show that while α-ImI targets the classical competitive ligand binding site in a subtype selective manner, α-ImII is a probe of a novel inhibitory site in homomeric α7 nAChRs.",
author = "Michael Ellison and Fan Gao and Wang, {Hai Long} and Sine, {Steven M} and McIntosh, {J. Michael} and Olivera, {Baldomero M.}",
year = "2004",
month = "12",
day = "28",
doi = "10.1021/bi048918g",
language = "English (US)",
volume = "43",
pages = "16019--16026",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "51",

}

TY - JOUR

T1 - α-conotoxins ImI and ImII target distinct regions of the human α7 nicotinic acetylcholine receptor and distinguish human nicotinic receptor subtypes

AU - Ellison, Michael

AU - Gao, Fan

AU - Wang, Hai Long

AU - Sine, Steven M

AU - McIntosh, J. Michael

AU - Olivera, Baldomero M.

PY - 2004/12/28

Y1 - 2004/12/28

N2 - The Conus peptides α-conotoxin ImI (α-ImI) and ImII (α-Imll) differ by only three of 11 residues in their primary sequences and yet are shown to inhibit the human α7 nicotinic acetylcholine receptor (nAChR) by targeting different sites. Mutations at both faces of the classical ligand binding site of the α7 nAChR strongly affect antagonism by α-ImI but not α-ImII. The effects of the mutations on α-ImI binding and functional antagonism are explained by computational docking of the NMR structure of α-ImI to a homology model of the ligand binding domain of the α7 nAChR. A distinct binding site for α-ImII is further demonstrated by its weakened antagonism for a chimeric receptor in which the membrane-spanning domains and intervening linkers of the α7 nAChR are replaced with the corresponding sequence from the serotonin type-3 receptor (5HT3). The two toxins also discriminate between different subtypes of human nicotinic receptors; α-ImII most strongly blocks the human α7 and α1β1δε receptor subtypes, while α-ImI most potently blocks the human α3β2 subtype. Collectively, the data show that while α-ImI targets the classical competitive ligand binding site in a subtype selective manner, α-ImII is a probe of a novel inhibitory site in homomeric α7 nAChRs.

AB - The Conus peptides α-conotoxin ImI (α-ImI) and ImII (α-Imll) differ by only three of 11 residues in their primary sequences and yet are shown to inhibit the human α7 nicotinic acetylcholine receptor (nAChR) by targeting different sites. Mutations at both faces of the classical ligand binding site of the α7 nAChR strongly affect antagonism by α-ImI but not α-ImII. The effects of the mutations on α-ImI binding and functional antagonism are explained by computational docking of the NMR structure of α-ImI to a homology model of the ligand binding domain of the α7 nAChR. A distinct binding site for α-ImII is further demonstrated by its weakened antagonism for a chimeric receptor in which the membrane-spanning domains and intervening linkers of the α7 nAChR are replaced with the corresponding sequence from the serotonin type-3 receptor (5HT3). The two toxins also discriminate between different subtypes of human nicotinic receptors; α-ImII most strongly blocks the human α7 and α1β1δε receptor subtypes, while α-ImI most potently blocks the human α3β2 subtype. Collectively, the data show that while α-ImI targets the classical competitive ligand binding site in a subtype selective manner, α-ImII is a probe of a novel inhibitory site in homomeric α7 nAChRs.

UR - http://www.scopus.com/inward/record.url?scp=11144331404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144331404&partnerID=8YFLogxK

U2 - 10.1021/bi048918g

DO - 10.1021/bi048918g

M3 - Article

VL - 43

SP - 16019

EP - 16026

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 51

ER -